Business Description
Belite Bio Inc
NAICS : 325412
SIC : 2834
ISIN : US07782B1044
Share Class Description:
BLTE: ADRTotal Employee Number:
41Description
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Equity-to-Asset | 0.98 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -54.6 | |||||
3-Year EPS without NRI Growth Rate | -22.2 | |||||
3-Year FCF Growth Rate | -23.2 | |||||
3-Year Book Growth Rate | 127.3 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.94 | |||||
9-Day RSI | 53.69 | |||||
14-Day RSI | 52.73 | |||||
3-1 Month Momentum % | -12.57 | |||||
6-1 Month Momentum % | -10.91 | |||||
12-1 Month Momentum % | 122.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.5 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -21.01 | |||||
ROA % | -20.56 | |||||
ROIC % | -35.53 | |||||
3-Year ROIIC % | -24.91 | |||||
ROC (Joel Greenblatt) % | -56.84 | |||||
ROCE % | -21.77 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 7.59 | |||||
Price-to-Tangible-Book | 7.61 | |||||
EV-to-EBIT | -58.53 | |||||
EV-to-EBITDA | -58.61 | |||||
EV-to-Forward-Revenue | 63.9 | |||||
EV-to-FCF | -149.27 | |||||
| Price-to-Net-Current-Asset-Value | 11.97 | |||||
Earnings Yield (Greenblatt) % | -1.71 | |||||
FCF Yield % | -0.62 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BLTE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Belite Bio Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.53 | ||
| Beta | -0.2762 | ||
| 3-Year Sharpe Ratio | 1.48 | ||
| 3-Year Sortino Ratio | 4.85 | ||
| Volatility % | 56.75 | ||
| 14-Day RSI | 52.73 | ||
| 14-Day ATR ($) | 7.298631 | ||
| 20-Day SMA ($) | 149.72175 | ||
| 12-1 Month Momentum % | 122.71 | ||
| 52-Week Range ($) | 59.12 - 200 | ||
| Shares Outstanding (Mil) | 40.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Belite Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Belite Bio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-10 16:30 | In 117 days | ||
| Third quarter earnings results for 2026 | 2026-11-10 | In 116 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-11 16:30 | In 26 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 25 days | ||
| General meeting for 2025 | 2026-07-15 | 146.68 (-0.24%) | ||
| Piper Sandler Virtual Ophthalmology Symposium | 2026-07-09 12:30 | 152.30 (-2.06%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 16:00 | 143.35 (+0.95%) | ||
| Guidance call for 2026 | 2026-05-26 12:30 | 137.30 (-3.17%) | ||
| First quarter earnings conference call for 2026 | 2026-05-20 16:30 | 139.70 (-2.53%) | ||
| First quarter earnings results for 2026 | 2026-05-20 | 139.70 (-2.53%) |
Show
Entries
Belite Bio Inc Frequently Asked Questions
What is Belite Bio Inc(BLTE)'s stock price today?
The current price of BLTE is $151.15. The 52 week high of BLTE is $200.00 and 52 week low is $59.12.
When is next earnings date of Belite Bio Inc(BLTE)?
The next earnings date of Belite Bio Inc(BLTE) is 2026-08-11 Est..
Does Belite Bio Inc(BLTE) pay dividends? If so, how much?
Belite Bio Inc(BLTE) does not pay dividend.
Guru Commentaries on NAS:BLTE
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Belite Bio Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers